TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.58 Million USD | 87.76% |
| 2022 | -29.31 Million USD | -2.04% |
| 2021 | -28.72 Million USD | -65.8% |
| 2020 | -17.32 Million USD | 23.53% |
| 2019 | -22.65 Million USD | 35.19% |
| 2018 | -34.95 Million USD | -83.0% |
| 2017 | -19.1 Million USD | 29.27% |
| 2016 | -27 Million USD | -10.64% |
| 2015 | -24.41 Million USD | -258.5% |
| 2014 | -6.8 Million USD | 11.66% |
| 2013 | -7.7 Million USD | -56.41% |
| 2012 | -4.92 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.16 Million USD | -821.64% |
| 2024 Q2 | -2.83 Million USD | 10.39% |
| 2023 Q1 | -10.88 Million USD | -50.46% |
| 2023 Q4 | 439 Thousand USD | -95.92% |
| 2023 FY | -3.58 Million USD | 87.76% |
| 2023 Q3 | 10.76 Million USD | 271.22% |
| 2023 Q2 | -6.28 Million USD | 42.24% |
| 2022 FY | -29.31 Million USD | -2.04% |
| 2022 Q4 | -7.23 Million USD | -11.4% |
| 2022 Q3 | -6.49 Million USD | -4.51% |
| 2022 Q2 | -6.21 Million USD | 34.41% |
| 2022 Q1 | -9.47 Million USD | -22.83% |
| 2021 Q2 | -8.93 Million USD | -76.52% |
| 2021 Q4 | -7.71 Million USD | -10.93% |
| 2021 Q1 | -5.06 Million USD | -17.47% |
| 2021 Q3 | -6.95 Million USD | 22.23% |
| 2021 FY | -28.72 Million USD | -65.8% |
| 2020 Q4 | -4.31 Million USD | -7.99% |
| 2020 Q1 | -4.02 Million USD | -2.16% |
| 2020 Q2 | -4.45 Million USD | -10.69% |
| 2020 Q3 | -3.99 Million USD | 10.31% |
| 2020 FY | -17.32 Million USD | 23.53% |
| 2019 FY | -22.65 Million USD | 35.19% |
| 2019 Q4 | -3.93 Million USD | 24.29% |
| 2019 Q2 | -6.32 Million USD | 12.3% |
| 2019 Q3 | -5.19 Million USD | 17.82% |
| 2019 Q1 | -7.21 Million USD | 7.0% |
| 2018 Q1 | -8.36 Million USD | -27.5% |
| 2018 Q4 | -7.75 Million USD | 14.63% |
| 2018 FY | -34.95 Million USD | -83.0% |
| 2018 Q3 | -9.08 Million USD | 6.86% |
| 2018 Q2 | -9.75 Million USD | -16.62% |
| 2017 Q3 | 1.17 Million USD | 117.82% |
| 2017 Q1 | -7.14 Million USD | -13.19% |
| 2017 Q2 | -6.56 Million USD | 8.13% |
| 2017 FY | -19.1 Million USD | 29.27% |
| 2017 Q4 | -6.56 Million USD | -660.68% |
| 2016 Q1 | -6.52 Million USD | 40.93% |
| 2016 FY | -27 Million USD | -10.64% |
| 2016 Q4 | -6.31 Million USD | -7.55% |
| 2016 Q3 | -5.87 Million USD | 29.24% |
| 2016 Q2 | -8.29 Million USD | -27.14% |
| 2015 Q2 | -2.92 Million USD | 26.88% |
| 2015 Q1 | -3.99 Million USD | -56.73% |
| 2015 FY | -24.41 Million USD | -258.5% |
| 2015 Q4 | -11.04 Million USD | -71.35% |
| 2015 Q3 | -6.44 Million USD | -120.71% |
| 2014 Q1 | -1.36 Million USD | 38.47% |
| 2014 Q2 | -980 Thousand USD | 27.99% |
| 2014 Q3 | -1.91 Million USD | -95.82% |
| 2014 Q4 | -2.54 Million USD | -32.83% |
| 2014 FY | -6.8 Million USD | 11.66% |
| 2013 Q1 | -1.53 Million USD | 0.0% |
| 2013 Q3 | -2.61 Million USD | -70.21% |
| 2013 FY | -7.7 Million USD | -56.41% |
| 2013 Q2 | -1.53 Million USD | 0.0% |
| 2013 Q4 | -2.21 Million USD | 15.28% |
| 2012 FY | -4.92 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -371.225% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 58.434% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 88.331% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 97.109% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 77.684% |
| Better Therapeutics, Inc. | -39.76 Million USD | 90.976% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 80.982% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 80.477% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 89.981% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 90.051% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 96.867% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -59.59% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 95.2% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 93.927% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 40.083% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 83.15% |
| Molecular Templates, Inc. | -8.12 Million USD | 55.835% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 76.359% |
| NexImmune, Inc. | -32.34 Million USD | 88.907% |
| Orgenesis Inc. | -55.36 Million USD | 93.519% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 85.797% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -4498.998% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 80.382% |
| Scopus BioPharma Inc. | -11.6 Million USD | 69.095% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 99.374% |
| Statera Biopharma, Inc. | -174.4 Million USD | 97.943% |
| Trevena, Inc. | -40.28 Million USD | 91.094% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -6202.034% |
| Vaccinex, Inc. | -20.25 Million USD | 82.282% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -203.525% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 92.973% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 53.865% |